- Home
- DFLI vs PULM Comparison
DFLI vs PULM Comparison
Compare DFLI & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DFLI | PULM |
|---|---|---|
| Founded | 2020 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0M | 5.2M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | DFLI | PULM |
|---|---|---|
| Price | $2.32 | $1.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 253.6K | 18.8K |
| Earning Date | 11-13-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.18 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $58,630,000.00 | $7,910,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $61.43 | $67.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 15.77 | ★ 5069.93 |
| 52 Week Low | $0.41 | $1.16 |
| 52 Week High | $5.15 | $4.98 |
Technical Indicators
Market Signals| Indicator | DFLI | PULM |
|---|---|---|
| Relative Strength Index (RSI) | 57.31 | 47.53 |
| Support Level | $1.85 | $1.41 |
| Resistance Level | $2.88 | $1.55 |
| Average True Range (ATR) | 0.26 | 0.10 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 53.67 | 35.75 |
Price Performance
Historical ComparisonAbout DFLI Dragonfly Energy Holdings Corp. (NV)
Dragonfly Energy Holdings Corp is engaged in the design, assembly, and sale of lithium-ion batteries, mainly lithium iron phosphate (LFP) batteries, for applications in recreational vehicles, marine, industrial, and other markets. The company operates through two segments: direct-to-consumer (DTC), which sells Battle Born branded batteries, and OEM, which supplies Dragonfly branded batteries to original equipment manufacturers.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).